MorphoSys Revenue and Competitors
Estimated Revenue & Valuation
- MorphoSys's estimated annual revenue is currently $162.7M per year.
- MorphoSys's estimated revenue per employee is $133,478
- MorphoSys's current valuation is $1.2B. (January 2022)
Employee Data
- MorphoSys has 1219 Employees.
- MorphoSys grew their employee count by 33% last year.
MorphoSys's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Head CMC (Large Molecules) | Reveal Email/Phone |
3 | VP, Business Operations & Innovation | Reveal Email/Phone |
4 | Head Global QA Operations | Reveal Email/Phone |
5 | VP, Head Global Patient Safety | Reveal Email/Phone |
6 | VP, US Head Human Resources | Reveal Email/Phone |
7 | Head ESO | Reveal Email/Phone |
8 | Executive Assistant to the Chief Legal Officer | Reveal Email/Phone |
9 | VP - Head Investor Relations | Reveal Email/Phone |
10 | Head R&D Operations & Excellence, Clinical Research & Development Organization | Reveal Email/Phone |
MorphoSys Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $176250M | 236276 | -1% | $1M | $2.3T |
#2 | $1.7M | 10 | N/A | N/A | N/A |
What Is MorphoSys?
MorphoSys is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates. MorphoSys is listed on the Frankfurt Stock Exchange and NASDAQ under the symbol MOR. Headquartered in Planegg near Munich, Germany and the MorphoSys group includs the fully owned U.S. subsidiary MorphoSys US Inc. based in Boston, MA.
keywords:N/A
N/A
Total Funding
1219
Number of Employees
$162.7M
Revenue (est)
33%
Employee Growth %
$1.2B
Valuation
N/A
Accelerator
MorphoSys News
According to Zacks, MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The...
Deutsche Bank Aktiengesellschaft set a 30.00 ($32.61) target price on MorphoSys in a research report on Tuesday, March 22nd. Berenberg Bank set...
Morphosys Ag (MOR) stock is down -70.35% over the last 12 months, and the average rating from Wall Street analysts is a Hold.
Media Release MorphoSys Announces Departure of Roland Wandeler Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys M ...
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Announces Departure of Roland Wandeler 09.11.2021 / 22:01 The issuer is solely responsible for the content of this announcement. Media Release MorphoSys Announces Departure of Roland Wandeler Planegg/Munich, Germany, November 9 ...